

**HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)**

**ROXADUSTAT AND ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF SYMPTOMATIC ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE**

**RED – RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST ONLY**

**NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING**

<b>Name: generic (trade)</b>	<b>What it is</b>	<b>Indication</b>	<b>Date decision last revised</b>	<b>Decision status</b>	<b>NICE / SMC Guidance</b>
Roxadustat <b>(Everenzo®)</b>	Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI).	Licensed for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease	September 2022	Final	NICE TA 807 recommended

**HWE APC recommendation:**

Roxadustat is recommended for restricted use as an option for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease in line with the recommendations in TA 807

<b>Name: generic (trade)</b>	<b>What it is</b>	<b>Indication</b>	<b>Date decision last revised</b>	<b>Decision status</b>	<b>NICE / SMC Guidance</b>
Erythropoiesis stimulating agents	Erythropoiesis stimulating agents	Licensed for the treatment of adult patients with symptomatic anaemia associated with chronic renal failure	September 2022	Final	NICE NG 203 recommended

**HWE APC recommendation:**

Erythropoiesis stimulating agents are recommended for restricted use as an option for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease in line with the recommendations in NG 203